Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HETRAZAN vs BILTRICIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Treatment of lymphatic filariasis (Wuchereria bancrofti, Brugia malayi),Treatment of tropical pulmonary eosinophilia,Treatment of loiasis (Loa loa)
Treatment of schistosomiasis (all species),Treatment of clonorchiasis sinensis (liver fluke),Treatment of opisthorchiasis (liver fluke),Off-label: Treatment of neurocysticercosis (in combination with corticosteroids),Off-label: Treatment of other trematode infections (e.g., fasciolopsiasis, intestinal flukes),Off-label: Treatment of cestode infections (e.g., diphyllobothriasis, taeniasis)
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Diethylcarbamazine is rapidly absorbed and extensively metabolized in the liver via N-oxidation and N-demethylation, involving multiple CYP enzymes. The major metabolite is diethylcarbamazine N-oxide.
Extensively metabolized by the liver, primarily by cytochrome P450 enzymes (CYP3A4), to inactive hydroxylated metabolites.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Protein binding is approximately 10-20%, primarily to albumin.
Approximately 80-85% bound to serum albumin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 90% due to well absorption from the gastrointestinal tract.
Oral bioavailability is approximately 80% due to extensive first-pass metabolism; higher with food.
No specific GFR-based dose modifications available; use with caution in renal impairment due to potential accumulation. Monitor for adverse effects.
No dosage adjustment required for any degree of renal impairment.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated.
No specific Child-Pugh based adjustments; contraindicated in hepatocellular carcinoma or history of hepatic encephalopathy; use caution in severe liver disease.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg. For children <15 kg, dosage based on 1 mg/kg initially, then increase gradually.
4 years and older: 60 mg/kg/day in 3 divided doses for 1 day; maximum single dose 2 g.
Initiate at lower end of dosing range (2 mg/kg per dose) due to potential age-related decrease in renal function. Monitor closely for adverse effects.
No specific adjustments; use standard adult dosing with monitoring for adverse effects.
HETRAZAN is contraindicated in patients with onchocerciasis (river blindness) due to the risk of severe Mazzotti reaction, including ocular damage and encephalopathy. Treatment should not be initiated in areas where onchocerciasis is endemic or in patients with suspected onchocerciasis.
None.
Severe allergic or inflammatory reactions (Mazzotti reaction) in patients with onchocerciasis; encephalopathy in loiasis with high microfilarial loads; ocular damage (e.g., uveitis, optic neuritis) in onchocerciasis; thrombocytopenia; aminotransferase elevations; use in pregnancy only if clearly needed.
Avoid grapefruit juice during treatment due to increased praziquantel exposure.,May cause transient neurologic symptoms in patients with cerebral schistosomiasis or neurocysticercosis due to inflammatory reaction around dying parasites.,Use with caution in patients with hepatic impairment (Child-Pugh class B or C) as metabolism may be reduced.,May exacerbate cysticercosis if used without corticosteroids in neurocysticercosis.,Potential for cardiac arrhythmias in patients with ventricular arrhythmias or electrolyte disturbances (rare).
Onchocerciasis (active or suspected),High-grade Loa loa microfilaremia (>8000 microfilariae/m L),Hypersensitivity to diethylcarbamazine or any component of the formulation
Hypersensitivity to praziquantel or any component of the formulation,Ocular cysticercosis (due to risk of irreversible ocular damage from inflammatory response),Concurrent use with rifampin (significantly reduces praziquantel plasma concentrations),Children under 1 year of age (safety not established)
Grapefruit juice may inhibit CYP450 metabolism; avoid concurrent intake. Administer with food to reduce gastrointestinal distress.
Take with food to enhance bioavailability. Avoid grapefruit juice as it may increase drug levels. Alcohol may worsen CNS side effects and is not recommended.
Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and third trimesters.
Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major malformations reported. Avoid in first trimester unless essential; use in second/third trimester if benefit outweighs risk.
Excreted into breast milk; M/P ratio unknown. Use with caution due to potential for adverse effects in infant.
Praziquantel is excreted into breast milk in small amounts; M/P ratio not established. After a single dose, milk levels low; consider pumping and discarding milk for 24-48 hours post-dose. Use with caution in nursing mothers.
No specific dose adjustments recommended; pharmacokinetics may be altered but data insufficient to guide changes.
No dose adjustment required for pregnancy; standard dosing (20 mg/kg three times daily for 1 day) unless hepatic impairment present. Pharmacokinetics in pregnancy not significantly altered; unchanged recommendations.
HETRAZAN (diethylcarbamazine) is primarily used for lymphatic filariasis and loiasis; monitor for Mazzotti reaction (fever, rash, arthralgias) in high microfilarial loads; contraindicated in onchocerciasis due to severe ocular reactions; administer with food to reduce GI upset.
Administer with food to increase absorption and reduce GI side effects. Use with caution in hepatic impairment; dose adjustment may be necessary. Monitor for neuropsychiatric effects (e.g., dizziness, headache) especially in patients with CNS involvement of schistosomiasis. Avoid in patients with ocular cysticercosis due to risk of intraocular inflammation; treat ocular lesions first with corticosteroids.
Take with food to minimize nausea.,Report any severe itching, rash, fever, or vision changes.,Complete full course even if symptoms improve.,Avoid grapefruit juice which may affect metabolism.,May cause dizziness or drowsiness; avoid driving if affected.
Take this medication with a meal to improve absorption and reduce stomach upset.,Do not chew or crush the tablets; swallow them whole.,Complete the full course of treatment even if you feel better.,You may experience dizziness, drowsiness, or headache; avoid driving or operating heavy machinery until you know how the drug affects you.,Inform your doctor if you have liver disease or are taking other medications.,Contact your doctor if you experience severe headache, seizures, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HETRAZAN vs BILTRICIDE, answered by our medical review team.
HETRAZAN is a Anthelmintic that works by Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.. BILTRICIDE is a Anthelmintic that works by Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HETRAZAN and BILTRICIDE depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HETRAZAN is: 2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.. The standard adult dose of BILTRICIDE is: 60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HETRAZAN and BILTRICIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HETRAZAN is classified as Category C. Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and thir. BILTRICIDE is classified as Category C. Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.